FANCD2 expression facilitates tumor immune escape in lung cancer by suppressing the immune microenvironment, while patients with high expression of FANCD2 exhibited higher tumor mutation burden (TMB) indicating greater responses to immunotherapy (Miao et al., 2022; Zhang et al., 2022). Here, FANCD2 is linked to neoplasm.